ImmunoGen’s Elahere Wins Big In Confirmatory Ovarian Cancer Trial

The company called MIRASOL’s reported OS benefit unprecedented and is gearing up to file for full FDA approval as well as EMA approval.

ImmunoGen announced data from the Phase III MIRASOL trial of Elahere in ovarian cancer • Source: Shutterstock

More from Clinical Trials

More from R&D